TABLE 4.

Effect of civamide treatment of latently infected guinea pigs on recurrent genital herpes

Study	Treatmenta	n	No. with recurrences	No. of days recurrences observedb between indicated days p.i.
				22–63	64–77	78–91
2b	BID for 10 days	15	15	4.0 ± 2.7c	1.4 ± 1.5	0.8 ± 1.2
	None	15	15	9.1 ± 3.5	1.4 ± 1.5	1.0 ± 1.2
3	BID for 10 days	15	15	4.2 ± 1.9c	1.1 ± 1.5	1.2 ± 1.2
	Once a wk for 5 wk	18	17	3.4 ± 2.1c	1.6 ± 1.3	0.9 ± 0.8
	1 dose	18	17	6.5 ± 4.2d	1.6 ± 1.7	0.9 ± 0.8
	None	18	18	9.9 ± 5.9	1.4 ± 1.3	1.6 ± 1.7

^aIntravaginal and topical 1.25% civamide beginning 21 days after intravaginal HSV-2 inoculation. BID, twice daily. 

^bMean ± standard deviation. 

^cP < 0.001 versus no treatment. 

^dP < 0.05 versus no treatment.